Chemically modified protein with polyethyleneglycol
The chemically modified protein of the present invention has a strong islet-activating activity and is lower in various side effects than non-modified IAP, so that it may be employed as a prevention and therapeutic drug for diabetes.
Y Nakagawa，T Ito - US
Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is &bgr;-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent....
N Katre，MJ Knauf - US
Biocompatible polymer conjugates
Pharmaceutically acceptable, non-immunogenic conjugates are formed by covalently binding a biologically inactive, natural polymer or derivative thereof to pharmaceutically pure, synthetic hydrophilic polymers via specific types of chemic...
バーグ,リチャード エイ.，マイケルズ,アラン エス.，マッカルラフ,キンバリー，...
IL-17 homologous polypeptide and therapeutic uses thereof
To provide a method of finding an amount of a polypeptide containing a specified amino acid sequence in a sample obtained from a mammalia and for measuring a level of an inflammatory enteropathy. ! The method is one for measuring the lev...
C Jian，E Filvaroff，S Fong，... - EP
Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
Polyethylene glycol serum immunoglobulin conjugates exhibit substantial rstance to degradation by intestinal enzyme while retaining their immuno-activity. Thus, PEG-IgG or PEG-IgA conjugates can be used as orally administered therapeutic...
C Cunningham-Rundles - US
Polyethylene-protein conjugates
The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of ...
J Hakini，P Kilian，P Rosen - US
APO-2 receptor
PROBLEM TO BE SOLVED: To provide a method for identification, isolation and recombination production of a new polypeptide named as Apo-2 and to provide an anti-Apo-2 antibody.
AVI J ASHKENAZI，KYUNG JIN KIM，ANAN CHUNTHARAPAI，...
Apo-2DcR
Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
Avi J. Ashkenazi，Kevin P. Baker，A Chuntharapai，...
Treatment of cancer using anti-Apo-2 antibodies
Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
CW Adams，AJ Ashkenazi，A Chuntharapai，... - US
WNT-1 Iinduced secreted polypeptide WISP-2
Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
DA Botstein，RL Cohen，AL Gurney，...
